C09BA09 - Fosinopril and Diuretics |
Probably not porphyrinogenic |
PNP |
Rationale
Fosinopril: No evidence of significant CYP-dependent metabolism. Two references stating (probable) non-porphyrinogenicity. Hydrochlorthiazide: Not metabolised. Probably no CYP-affinity. Clinical experience of non-porphyrinogenicity. Conflicting evidence.
Chemical description
Fosinopril: Hydrolyzed by esterases in the liver to fosinoprilate, an ACE-inhibitor. Of this 75% is excreted in unchanged form by the kidneys, 20-30% as glucuriode conjugate and 1-5% as p-hydroxy metabolite.
Hydrochlorthiazide: thiazide diuretic, sulfonamide congener. Eliminated in urine in unchanged form. Probably no CYP-affinity.
Personal communication
Hydrochlorthiazide:
Thunell, patient report (n=1): tolerated.
Andersson, patient reports (n=10): tolerated.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
Similar drugs
References
| # | Citation details | PubMed ID |
|---|---|---|
| Porphyria Drug Lists | ||
| 1. | Australian List
Australian Porphyria Association No longer maintained
|
|
| 2. | French List
Centre Français des Porphyries
|
|
| 3. | EPI List
European Porphyria Initiative No longer maintained
|
|
| 4. | South African List
Porphyria South Africa No longer maintained
|
|
Tradenames
Fosinoprilnatrium / Hydrochloorthiazide 
Fosinopril Hctz 
Fosinopril / Hidroclorotiazida · Fosinopril /Hidroclorotiazida · Fositens Plus 
Duopril · Fosicard Plus 
Fosicombi · Fosinopril e Idroclorotiazide · Tensozide 
Fosinopril-HCT 
Fosinopril e Idroclorotiazide · Fosinopril HCT · Fosinopril/HCT · Monozide 
Fosinopril HCT 
Monopril 
Monopril plus 
Fosicard HCT · Monopril Plus · Monotens HCT 
Monace